drugset / Trial / NCT01020006
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients receiving concurrent therapy with intravenously administered gemcitabine for 12 weeks.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | PCI-27483 | Small molecule | 0.8 mg/kg | Subcutaneous |
| Subject | PCI-27483 | Small molecule | 1.2 mg/kg | Subcutaneous |
| Subject | PCI-27483 | Small molecule | 1.5 mg/kg | Subcutaneous |